Form 4: Zenas BioPharma Director Hongbo Lu Acquires Shares
SEC Form 4 Filing
Director Hongbo Lu reports the acquisition of 58,823 shares of Zenas BioPharma through an indirect holding.
Summary
- On September 13, 2024, Hongbo Lu, a director of Zenas BioPharma, indirectly acquired 58,823 shares of common stock at a price of $17 per share.
- The shares are held by NEXTBio Master Fund LP, with potential indirect beneficial ownership attributed to NEXTBio Capital LLC, NEXTBio Capital Management LP, and Hongbo Lu.
- Lu disclaims beneficial ownership except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of share acquisition.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.
Stakeholder Impact
- The acquisition of shares by a director could be viewed positively by shareholders, indicating confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 09/13/2024 | Date of transaction: Acquisition of shares. |
| 09/17/2024 | Date of signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.